FY26
Assets1,780.79
Net Worth1,149.59
Total Debt387.91
RevenueAnnualised basis869.14
EBITDAAnnualised basis231.97
PATAnnualised basis109.90
EBITDA Margin (%)26.69
At a glance
Updated 2026-09-06 23:53:51Symbiotec Pharmalab is a Mainboard IPO with an issue size of ₹1,757.00 crore, proposed for listing on BSE, NSE. The issue structure includes a fresh issue of ₹150.00 crore and an offer-for-sale component of ₹1,607.00 crore.
Issue details
Listing atNSE EMERGE
Issue typeBook Build Issue
Issue size₹1.00 Cr
Fresh issue₹150.00 Cr
Offer for sale₹1,607.00 Cr
Face value₹2
Price band₹988.00–₹988.00
Allotment28 Aug 2026
Listing1 Sep 2026
Listing performance
Full performance ↗Issue price₹988.00
Listing price₹988.00
Current price₹1.00
Listing gain0.00%
Current return11.10%
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹185.00
GMP / upper price18.72%
Est. listing₹1,173.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens24 Aug 2026
Closes27 Aug 2026
Allotment28 Aug 2026
Listing1 Sep 2026
Subscription demand
Full bidding ↗QIB181.20×
sHNI58.01×
bHNI87.34×
NII / HNI87.34×
Retail13.69×
Total71.26×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹192,660 |
| S-HNI (Min) | 14 | 210 | ₹207,480 |
| S-HNI (Max) | 67 | 1005 | ₹992,940 |
| B-HNI (Min) | 68 | 1020 | ₹1,007,760 |
Reservation
Issue mix
QIB49.91%88,76,517 shares
− Anchor Investor29.94%53,25,909 shares
− QIB (Ex. Anchor)19.96%35,50,608 shares
NII (HNI)14.97%26,62,955 shares
− bNII > ₹10L9.98%17,75,303 shares
− sNII < ₹10L4.99%8,87,652 shares
Retail34.93%62,13,562 shares
Preferential Reservations
Employee0.19%33,408 shares
Total100.00%1,77,86,442 shares
Company
Incorporated2002
Use of proceeds
| Object | Amount |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings | ₹112.50 Cr |
| General corporate purposes | — |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Assets989.99₹ Cr · -23.5% vs prior year
Net Worth621.44₹ Cr · -13.1% vs prior year
FY25
Assets1,579.65
Net Worth814.71
Total Debt540.92
RevenueAnnualised basis751.55
EBITDAAnnualised basis206.11
PATAnnualised basis96.78
EBITDA Margin (%)27.42
FY24
Assets1,294.78
Net Worth714.84
Total Debt247.20
RevenueAnnualised basis716.25
EBITDAAnnualised basis177.04
PATAnnualised basis100.05
EBITDA Margin (%)24.72
FY23
Assets989.99
Net Worth621.44
Total Debt217.87
RevenueAnnualised basis566.15
EBITDAAnnualised basis74.25
PATAnnualised basis23.49
EBITDA Margin (%)13.11
KPIs
| KPI | Mar 31, 2025 | Mar 31, 2026 |
|---|---|---|
| ROE | 12.66% | 11.19% |
| ROCE | 11.80% | 11.56% |
| RoNW | 11.79% | 9.48% |
| PAT Margin | 12.80% | 12.60% |
| EBITDA Margin | 27.26% | 26.59% |
| Price to Book Value | 6.58 | 5.35 |
Valuation & shareholding
Pre-IPO EPS17.82
Post-IPO EPS17.39
Pre-IPO P/E55.44
Post-IPO P/E56.81
Promoter holding pre34.47%
Promoter holding post0.00%
Market cap₹6244.43 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Symbiotec Pharmalab IPO | — | 61.88 x | — | — |
| Sai Parenteral's IPO | — | 111.58 x | — | — |
| Corona Remedies IPO | — | 35.15 x | — | — |
| Sudeep Pharma IPO | — | 53.55 x | — | — |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Location
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-06 23:53:51.
IPO UPDATE ALERTS
Register for IPO Updates →Track Symbiotec Pharmalab without missing an update
Register for subscription, GMP, allotment and listing notifications.